AIMMUNE THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
AIMMUNE THERAPEUTICS INC. - More news...
AIMMUNE THERAPEUTICS INC. - More news...
- Aimmune’s PALFORZIA®▼ [defatted powder of Arachis hypogaea L., semen (peanuts)] Receives Final Appraisal Determination (FAD) as Positive Draft Guidance From NICE for the Treatment of Peanut Allergy in Patients Aged 4 to 17 Years
- Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 Years
- European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT
- AIMMUNE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aimmune Therapeutics Inc. - AIMT
- SHAREHOLDER ALERT: WeissLaw LLP Investigates Aimmune Therapeutics, Inc.
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Aimmune Therapeutics, Inc.
- (AIMT) Alert: Johnson Fistel Investigates Proposed Sale of Aimmune Therapeutics; Is $34.50 a Fair Price?
- Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science
- Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
- Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
- Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
- Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
- Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
- Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
- Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
- Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
- Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights
- Aimmune Therapeutics to Present at Upcoming Investor Conferences
- Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
- Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
- Aimmune to Present at the Cantor Global Healthcare Conference
- FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut Allergy
- Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy
- Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights
- Aimmune to Present at the JMP Securities Life Sciences Conference
- U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
- Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
- Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics — Discovering Underlying Factors of Influence
- Former Aimmune Therapeutics CEO: Taking Stock in Allergies | Mad Money | CNBC